

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2801-18

C# M#

BOTTAZZI et al.

JAN 21 2005

TC/A.U.

1644

Serial No. 09/555,473

Examiner: NOLAN

Filed: February 26, 2002

Date: January 21, 2005

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN
PTX3Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$50.00 \$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$200.00 \$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add
\$360.00 (1051)/\$180.00 (2051) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s)

One Month Extension \$120.00 (1251)/\$60.00 (2251)
Two Month Extensions \$450.00 (1252)/\$225.00 (2252)
Three Month Extensions \$1020.00 (1253)/\$510.00 (2253)
Four Month Extensions \$1590.00 (1254)/\$795.00 (2254) \$ 120.00

Terminal disclaimer enclosed, add \$130.00 (1814)/\$65.00 (2814) \$

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806) \$

Assignment Recording Fee \$40.00 (8021) \$

Other: \$

TOTAL FEE ENCLOSED \$ 120.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:ppNIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BOTTAZZI et al.

Atty. Ref.: 2801-18

Serial No. 09/555,473

Group: 1644

Filed: February 26, 2002

Examiner: NOLAN

For: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN
PTX3

* * * * *

January 21, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

01/25/2005 FFANAIA2 00000025 09555473

01 FC:1251

120.00 DP

RESPONSE

Responsive to the Office Action dated September 23, 2004, entry and consideration of the following remarks are requested, the period for response having been extended up to and including Monday, January 24, 2005, by submission of the requisite petition and fee, attached.

The Section 103 rejection of claims 17-19 over Breviario (JBC Vol. 267, No. 31, pp 22190-22197, 1992), in view of U.S. Patent No. 6,344,320 (Rothschild), is traversed. Reconsideration and withdrawal of the rejection are requested in view of the following comments.

The present application claims an orally, parenterally, transdermally or subcutaneously administrable pharmaceutical composition containing as an active ingredient the amino acid sequence of the long pentraxin PTX3 having sequence SEQ ID NO: 1, and a pharmaceutically acceptable excipient.